Navigation Links
Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
Date:6/19/2009

dification or additional methods may need to be developed, the success of which is not assured, due to possible future changes in the L-DOS47 formulation or manufacturing process, requirements of regulatory authorities, or other factors; the need to further upscale the manufacturing process for the Company's drug candidates and the risk that further upscaling may not be achieved within the timelines expected by the Company or at all; the need for regulatory approvals, which may not be obtained in a timely manner or at all; the need for clinical trials, the occurrence and success of which cannot be assured; intellectual property risks; marketing/manufacturing risks and partnership/strategic alliance risks, including Helix's dependency on KBI Biopharma Inc. and its other contractors, consultants and advisors, whose performance and interdependence can critically affect the Company's performance and the achievement of its milestones; product liability risks; the effect of competition; the risk of technical obsolescence; and the risk of changes in business strategy or development plans. Such risks and uncertainties, and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information, are more fully described in the Company's latest Annual Information Form, MD&A and other reports filed with the Canadian Securities Regulatory Authorities from time to time at www.sedar.com, and in the Company's Form 20-F and other reports filed with the U.S. SEC from time to time (see www.sec.gov/edgar.shtml). Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should tho
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
2. Helix BioPharma to Present at the BioFinance 2009 Conference
3. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
4. Helix BioPharma Announces Q2 2009 Financial Results
5. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
6. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Announces Q1 2009 Financial Results
9. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
10. Helix BioPharma Corp. Announces Fiscal 2008 Results
11. Helix Biopharma Closes $11.4 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015 VG Life Sciences, ... for autoimmune and infectious diseases, announced that the ... an important new composition of matter patent covering ... targeting of CLIP. U.S. Patent ... VG Life Sciences, VG1177, a synthetic peptide which ...
(Date:3/2/2015)... Global Stem Cells Group.com ... Shenzhen HANK Bioengineering Co., Ltd. and its Chinese-American ... establish a stem cells training course in the ... 2015. , Shenzhen HANK is a biotechnology company ... microbiologist and virologist, to integrate research, development, production, ...
(Date:3/1/2015)... London, UK (PRWEB) March 01, 2015 ... a partnership agreement for quality market research promotion ... and sell research reports worked out by DataGroup ... Department at Market Publishers Ltd, commented on the ... to have DataGroup Booksellers in our team of ...
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. (“Immunovaccine” ... of a fraudulent press release disseminated this morning by ... from Immunovaccine. This press release states that Immunovaccine has ... The press release did not originate from Immunovaccine ... within the press release. Please note that all ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Immunovaccine Disclaims Hoax Press Release 2
... ... Arlington, VA, will discuss practical approaches to President Obama’s challenges to "find the needle ... ... to connect the dots” on the Christmas bomber in his recent address to the ...
... new antimalarial drugs after discovering the normal function of ... protein, which causes resistance to the front-line drug chloroquine. ... the malarial chloroquine-resistance factor. The study examined transporter ... cell. The genes for these proteins are present in ...
... SAN DIEGO, Jan. 11 BioMed Realty Trust, Inc. (NYSE: ... subsidiary, BioMed Realty, L.P., has completed its previously announced private ... The company also announced that the initial purchasers fully exercised ... in a total sale of $180 million in aggregate principal ...
Cached Biology Technology:NDIA's Biometrics Conference to Address Practical Approaches to the President's Challenge of 'Connecting the Dots' and Implementing $1B for New and Additional Security 2Discovery provides new drug targets for malaria cure 2BioMed Realty, L.P. Completes $180 Million Offering of 3.75% Exchangeable Senior Notes, Including Full Exercise of Initial Purchasers' Over-Allotment Option 2BioMed Realty, L.P. Completes $180 Million Offering of 3.75% Exchangeable Senior Notes, Including Full Exercise of Initial Purchasers' Over-Allotment Option 3
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... CHAMPAIGN, lll. A protein that helps pack DNA ... gene activity, scientists report. The researchers found that the protein, ... the cellular workbenches on which all proteins are made. ... of Cell Biology . A human cell,s genetic material ...
... fishes in the ocean,s deepest reachesthe hadal zone, below 6000 ... numerous at such depths than experts had thought. The authors ... of BioScience , observed 10 to 20 snailfish congregating ... lander in the Japan Trench. The observation period lasted only ...
... atmospheric carbon dioxide levels rise, so does the pressure on ... citizens is that plants will absorb some of the extra ... For a few decades now, researchers have hypothesized about one ... the CO 2 they take up from the atmosphere. ...
Cached Biology News:Histone H1 regulates gene activity throughout the cell cycle 2Histone H1 regulates gene activity throughout the cell cycle 3Study suggests more fish than thought may thrive in the ocean's depths 2Nitrogen pollution alters global change scenarios from the ground up 2Nitrogen pollution alters global change scenarios from the ground up 3
... for 25 chips provides the chips and ... (at nanogram levels) with the Experion automated ... StdSens microfluidic chips, 2 x 1,250 microliters ... StdSens stain, 2 x 20 microliters RNA ...
...
... Accuri's C6 Flow Cytometer System is a full ... system including: the C6 Flow Cytometer, CFlow Software, ... C6 Flow Cytometer System provides all the capabilities ... fraction of the price. The C6 Flow Cytometer ...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: